Table 1: Classifications of RCC
Table 2: TNM and Staging Classification System for RCC
Table 3: Symptoms of RCC
Table 4: Risk Factors and Comorbidities for RCC
Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages =20 Years, 1993–2007
Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages =20 Years, 1993–2007
Table 7: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages =20 Years, 1993–2007
Table 8: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages =20 Years, 1993–2007
Table 9: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993–2007
Table 10: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases
Table 11: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases
Table 12: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis
Table 13: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages =20 Years, N, 2013–2023
Table 14: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013
Table 15: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages =20 Years, N (Row %), 2013
Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages =20 Years, N, 2013–2023
Table 17: Treatment Guidelines for RCC
Table 18: Most Prescribed Drugs for RCC by Class in the 8MM
Table 19: Country Profile – US
Table 20: Country Profile – France
Table 21: Country Profile – Germany
Table 22: Country Profile – Italy
Table 23: Country Profile – Spain
Table 24: Country Profile – UK
Table 25: Country Profile – Japan
Table 26: Country Profile – China
Table 27: Leading Treatments for RCC, 2015
Table 28: Product Profile – Sutent (sunitinib)
Table 29: Results of the Trial Comparing Sutent Versus IFN-alfa
Table 30: Summary of AEs from the Trial of Sutent Versus IFN-alfa
Table 31: Sutent SWOT Analysis, 2014
Table 32: Global Sales Forecasts ($m) for Sutent 2013–2023
Table 33: Product Profile – Nexavar (sorafenib)
Table 34: Results of the Trial Comparing Nexavar Versus Placebo
Table 35: Summary of AEs from the Trial of Nexavar versus Placebo
Table 36: Nexavar SWOT Analysis, 2014
Table 37: Global Sales Forecast ($m) for Nexavar, 2013-2023
Table 38: Product Profile – Votrient (pazopanib)
Table 39: Results of the Trial Comparing Votrient Versus Placebo
Table 40: Summary of the Results of the Trials Comparing Votrient Versus Sutent
Table 41: Summary of AEs from the Trial of Votrient Versus Sutent
Table 42: Votrient SWOT Analysis, 2014
Table 43: Global Sales Forecast ($m) for Votrient, 2013-2023
Table 44: Product Profile – Avastin (bevacizumab)
Table 45: Results of the Trial Comparing Avastin + IFN-alfa Versus IFN-alfa + Placebo
Table 46: Summary of AEs from the Trial of Avastin + IFN-alfa Versus IFN-alfa + placebo
Table 47: Avastin SWOT Analysis, 2014
Table 48: Global Sales Forecasts ($m) for Avastin, 2013-2023
Table 49: Product Profile – Torisel (temsirolimus)
Table 50: Results of the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa
Table 51: Summary of AEs from the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa
Table 52: Torisel SWOT Analysis, 2014
Table 53: Global Sales Forecasts ($m) for Torisel, 2013-2023
Table 54: Product Profile – Inlyta (axitinib)
Table 55: Results of the Trial Comparing Inlyta Versus Nexavar
Table 56: Summary of AEs from the Trial Comparing Inlyta Versus Nexavar
Table 57: Inlyta SWOT Analysis, 2014
Table 58: Global Sales Forecasts ($m) for Inlyta, 2013-2023
Table 59: Product Profile – Afinitor (everolimus)
Table 60: Results of the Record-1 Trial Comparing Afinitor Versus Placebo
Table 61: Summary of AEs from the Trial Comparing Afinitor Versus Placebo
Table 62: Afinitor SWOT Analysis
Table 63: Global Sales Forecasts ($m) for Afinitor, 2013-2023
Table 64: Results of the Trial Comparing IFN-alfa Versus IFN-alfa + vinblastine
Table 65: Summary of AEs from the Trial of IFN-alfa
Table 66: Results of the Trial Comparing High-Dose IL-2 Versus IL-2 + IFN-alfa
Table 67: Summary of AEs from the High-Dose IL-2 Versus IL-2 + IFN-alfa Trial
Table 68: Selected placebo-controlled, randomized adjuvant RCC trials
Table 69: Comparison of Therapeutic Classes in Development for RCC, 2016
Table 70: Product Profile – Opdivo (nivolumab)
Table 71: Product Profile – Yervoy (imilimumab)
Table 72: Efficacy of Opdivo in the CheckMate 025 Trial
Table 73: Efficacy of Opdivo + Yervoy, Opdivo + Stutent, and Opdivo + Votrient
Table 74: Safety of Opdivo and Afinitor from the CheckMate 025 Trial
Table 75: Safety Profile of Opdivo + Yervoy, Opdivo + Sutent, and Opdivo + Votrient
Table 76: Opdivo (monotherapy or combination with Yervoy) SWOT Analysis, 2016
Table 77: Global Sales Forecasts ($M) for Opdivo, 2013–2023
Table 78: Product Profile – Atezolizumab
Table 79: Efficacy of Atezolizumab
Table 80: Efficacy of Atezolizumab + Avastin combination therapy
Table 81: Safety of Atezolizumab in Phase Ib Study
Table 82: Atezolizumab SWOT Analysis, 2016
Table 83: Global Sales Forecasts ($M) for Atezolizumab, 2013–2023
Table 84: Product Profile – Cometriq (cabozantinib)
Table 85: Efficacy of Cometriq in the Phase III METEOR Trial
Table 86: Safety of Cometriq
Table 87: Cometriq SWOT Analysis, 2016
Table 88: Global Sales Forecasts ($M) for Cometriq, 2013–2023
Table 89: Product Profile – IMA901
Table 90: Efficacy of IMA901 in the Phase III IMPRINT Trial
Table 91: Product Profile – AGS-003
Table 92: AGS-003 SWOT Analysis, 2016
Table 93: Global Sales Forecasts ($M) for AGS-003, 2013–2023
Table 94: Product Profile – Tivozanib
Table 95: Efficacy of Tivozanib
Table 96: Safety of Tivozanib
Table 97: Safety profile of Tivozanib over time
Table 98: Tivozanib SWOT Analysis, 2016
Table 99: Global Sales Forecasts ($M) for Tivozanib, 2013–2023
Table 100: Product Profile – Lenvima (lenvatinib)
Table 101: Efficacy of Lenvima
Table 102: Lenvima SWOT Analysis, 2016
Table 103: Global Sales Forecasts ($M) for Lenvima, 2013–2023
Table 104: Product Profile – Avelumab
Table 105: Avelumab (in combination with Inlyta) SWOT Analysis, 2016
Table 106: Global Sales Forecasts ($M) for Avelumab, 2013–2023
Table 107: Drug Candidates in Early Development, 2016
Table 108: Key Companies in the RCC Market in the 8MM, 2013–2023
Table 109: Pfizer’s RCC Portfolio Assessment, 2016
Table 110: Novartis’ RCC Portfolio Assessment, 2016
Table 111: Bayer’s RCC Portfolio Assessment, 2016
Table 112: Roche’s RCC Portfolio Assessment, 2016
Table 113: BMS’ RCC Portfolio Assessment, 2016
Table 114: Merck & Co.’s RCC Portfolio Assessment, 2016
Table 115: Exelixis’ RCC Portfolio Assessment, 2016
Table 116: Eisai RCC Portfolio Assessment, 2016
Table 117: AVEO Oncology’s RCC Portfolio Assessment, 2016
Table 118: Argos Therapeutics’ RCC Portfolio Assessment, 2016
Table 119: Sales Forecasts ($m) for Renal Cell Carcinoma in the Global Markets, 2013-2023
Table 120: RCC Market Drivers and Barriers, 2013–2023
Table 121: Sales Forecasts ($m) for Renal Cell Carcinoma in the United States, 2013–2023
Table 122: Key Events Impacting Sales for RCC in the US, 2016
Table 123: US RCC Market Drivers and Barriers, 2016
Table 124: Sales Forecasts ($m) for Renal Cell Carcinoma in 5EU, 2013–2023
Table 125: Key Events Impacting Sales for RCC in 5EU, 2016
Table 126: 5EU RCC Market Drivers and Barriers, 2016
Table 127: Sales Forecasts ($m) for Renal Cell Carcinoma in Japan, 2013–2023
Table 128: Key Events Impacting Sales for RCC in Japan, 2016
Table 129: Japan RCC Market – Drivers and Barriers, 2016
Table 130: Sales Forecasts ($m) for Renal Cell Carcinoma in China, 2013–2023
Table 131: Key Events Impacting Sales for RCC in China, 2016
Table 132: China RCC Market – Drivers and Barriers, 2016
Table 133: RCC Incidence, 2013–2023
Table 134: RCC, Key Launch Dates
Table 135: RCC, Key Patent Expiries
Table 136: Average Body Weight and Surface Area Across the 8MM
Table 137: Average Cost of Therapy of Sutent
Table 138: Average Cost of Therapy of Votrient
Table 139: Average Cost of Therapy of Nexavar
Table 140: Average Cost of Therapy of Avastin
Table 141: Average Cost of Therapy of Inlyta
Table 142: Average Cost of Therapy of Torisel
Table 143: Average Cost of Therapy of Afinitor
Table 144: Average Cost of Therapy of Opdivo
Table 145: Average Cost of Therapy of Yervoy + Opdivo
Table 146: Average Cost of Therapy of Atezolizumab
Table 147: Average Cost of Therapy of Avelumab
Table 148: Average Cost of Therapy of Cometriq
Table 149: Average Cost of Therapy of Lenvima
Table 150: Average Cost of Therapy of tivozanib
Table 151: Average Cost of Therapy of AGS-003
Table 152: High-Prescribing Physicians (non-KOLs) Surveyed, By Country